TandemAI Raises $35 million

TandemAI, a technology company focused on transforming drug discovery infrastructure, announced it has raised $35 million in a Series A financing to expand its drug discovery service platform that integrates breakthrough computational tools with wet lab biophysics, medicinal chemistry, and biology.

Qiming Venture Partners led the financing along with participation from OrbiMed, Eight Roads Ventures, and F Prime Capital.

 

“TandemAI has developed a compelling vision for drug discovery that leverages both best-in-class experimental and computational technologies,” said Jarlon Tsang, Managing Partner and Head of China for Eight Roads. “Significantly, their integrated approach streamlines the discovery workflow and enables access to state-of-the-art computational tools to biotechnology companies at any stage and any scale. They have assembled a world-class team that is executing on that vision.”  

 

“The financing is a strong endorsement of our strategy, value proposition, and the progress we have made to date,” said Jeff He, MBA, co-founder and CEO of TandemAI. “The funds will allow us to increase our wet lab capacity to over 500 chemists and biologists and continue development of our world class computational tools to service the expanding biotech client base in the U.S. and China.” He noted the company’s client base currently includes about fifty companies.

 

TandemAI was established in late 2021 with a mission to lower the barrier to entry to the most advanced tools in drug discovery, including physics-based molecular simulation, artificial intelligence, and access to supercomputing infrastructure. The company’s fully integrated pre-clinical drug discovery platform is designed to empower researchers to discover better therapeutic candidates faster and more efficiently by democratizing access to the most innovative tools in drug discovery. The goal is to dramatically improve the success rate of pre-clinical therapeutic candidates and, ultimately, help improve the lives of people waiting for new treatment options.

 

The company completed $25 million Seed and pre-Series A financing in late 2021.

シェア

本ウェブサイトに記載されている情報は、ベンチャーキャピタル投資を求める起業家や企業に資する目的においてのみ提供されています。Eight Roadsは、投資助言サービスを提供することを申し出ているものではなく、また証券取引に関与することを申し出ているものでもありません。